M75.0 M75.1 M75.2 M75.3 M75.4 M75.5 M75.8 M75.9
Conditions
Interventions
Group 1: Preliminary Examination (as part of the routine examination when presenting at the LKH):
1) Shoulder x-rays (a / p, axial), 1x
2) Ultrasound of the rotator cuff, 1x
3) Orthopedic pain provoca
Sponsors
FH Gesundheitsberufe OÖ
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: For inclusion in study participation, points a) b) and c) must apply! a) At least three of the six compulsory orthopedic stress tests are positive b) The patient can repeatedly provoke pain by an active movement or by an active position (= functional DEMO) c) At least ONE of the following diagnoses apply to the patient: - Subacromial pain syndrome - Periarthropathia humero-scapularis - Unspecific shoulder pain (Dolores omi / Omalgie) - Frozen Shoulder (primary and secondary) - shoulder impingement syndrome, grade 1-3 (grade 3 only in partial rupture of the rotator cuff) - Tendinitis of the rotator cuff - Tendinitis calcarea of ??the rotator cuff - Tendinitis of the long biceps tendon - subacromial bursitis - Bursitis calcarea subacromialis - Partial ruptures of the rotator cuff - Unspecific degeneration of the rotator cuff
Exclusion criteria
Exclusion criteria: Exclusion criteria: - Complete rupture of the rotator cuff (US or MRI or Arthro-MRI or arthroscopy confirmed) - SLAP lesion type II / III / IV (Arthro-MRI or arthroscopy confirmed) - Pulley lesion (US or MRI or Arthro-MRI or arthroscopically confirmed) - Osteochondrosis of one or more joints of the shoulder complex - osteoarthritis (from stage 2; - Omarthritis (rheumatoid arthritis, purulent arthritis, tuberculous arthritis) - humeral head nekrosis - fractures of the bones involved in the shoulder complex less than 12 months ago - Artificial joint replacement of one or more components of the glenohumeral joint - Surgery on one or more joints or soft tissue structures of the shoulder complex less than 12 months ago - Habitual shoulder dislocation - status post shoulder luxation (event less than 6 months ago or more often than once dislocated) - Tumor events in the body area to be treated (shoulder quadrant) - advanced osteoporosis - hemophilia - fibromyalgia - Not completely healed wounds in the treatment area (shoulder quadrant) - Keloids in the treatment area (shoulder quadrant) - neurological / neuromuscular / neuropsychological underlying disease or neuropathological event (central / radicular / peripheral nerve lesions) - Acute or chronic mental illness, which possibly excludes a sane behavior of the subject or demonstrably favors a self- or foreign-endangering behavior - insufficient verbal communication - e.g. because of linguistic barriers - between proband and therapist - Limitations of mental functions that make participation in the study significantly more difficult - Oral use or other administration of opioid painkillers, which can not be discontinued at least 7 days before the start of the study, OR is not expected to be maintained throughout the study period (6-8 days) in the same (!) dosage and dosage form - Other on-going therapies that are likely to be suspected to affect the disease being studied (all conventional and complementary therapies and treatments included) and that may not be terminated or suspended for the duration of the study at least one week prior to the beginning of the study (first appointment) - Participation in another medical study within the last three months or during the study period of this study Relative exclusion criteria: - Ongoing blood thinning medication --> Subjects are informed that some side effects (see Study-Specific Risks and Side Effects) may be more pronounced (for example, increased hematoma formation) when taking blood-thinning medications. Since no other severe health damage is to be expected from this, the test subjects can still participate in the study if they want to accept the higher risks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pain intensity (VAS) in the functional DEMO immediately after treatment and after 6-8 days compared to baseline [percent] Determination of the VAS in the previously defined reference position (photo / video documentation of the functional DEMO) immediately after treatment and after 6-8 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the pain-free ROM (degree °) immediately after treatment and after 6-8 days [percent] Measurement of the active range of motion in a pain-free area using goniometry in fixed measuring positions immediately after treatment and after 6-8 days | — |
Countries
Austria
Contacts
Public ContactPatrick Rudelstorfer
FH Gesundheitsberufe OÖ
Outcome results
None listed